- Home
- » Tags
- » Resminostat
Top View
- First-In-Human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
- Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
- First-In-Human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
- Synopsis Clinical Study Report
- GSK3B Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties and Is a Novel Drug Target for Triple-Negative Breast Cancer
- Histone Deacetylase Inhibitors for CTCL
- Histone Deacetylase Inhibitor Resminostat in Combination with Sorafenib Counteracts Platelet-Mediated Pro-Tumoral Effects In
- Histone Deacetylases
- COMP Agenda of the 11-13 September 2018 Meeting
- Upregulation of PDL1 Expression by Resveratrol and Piceatannol in Breast and Colorectal Cancer Cells Occurs Via HDAC3/ P300-Mediated Nfkappab Signaling
- Combination of the Deacetylase Inhibitor Panobinostat and The
- WO 2019/040491 Al 28 February 2019 (28.02.2019) W 1P O PCT
- Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-Hdacis) in the Treatment of Solid Malignancies
- Histone Deacetylase Inhibitors for Cancer Therapy: an Evolutionarily Ancient Resistance Response May Explain Their Limited Success
- Articles from the 16Th International Conference on Malignant
- Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
- Resminostat | Medchemexpress
- Novel Molecular Targets in Hepatocellular Carcinoma
- Advances in Epigenetic Cancer Therapeutics
- BRDT Promotes Ovarian Cancer Cell Growth Ling Chen1, Shang Cai2,Jing-Meiwang1,Ying-Yinghuai3,Pei-Hualu4 and Qian Chu3
- (2006.01) Ao, At, Au, Az, Ba, Bb, Bg, Bh, Bn, Br, Bw, By, Bz, 10
- (51) International Patent Classification: (72) Inventors: DRAKE, Adam
- HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1
- International Application Number: PCT/US20 19/035464 (22)
- Age-Dependent Fecundity of Podisus Nigrispinus
- Recent Developments in Epigenetic Cancer Therapeutics: Clinical Advancement and Emerging Trends Kunal Nepali1 and Jing‑Ping Liou1,2*
- Activity of Epigenetic Inhibitors Against Babesia Divergens
- Non-Coding DNA in IBD: from Sequence Variation in Gut: First Published As 10.1136/Gutjnl-2018-317516 on 28 January 2019
- Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats
- Histone Deacetylase Inhibitors: Recent Outcomes from Clinical Trials and the Implications for Oncology Treatment Approaches
- Emerging Role of Histone Deacetylase Inhibitors As Anti-Breast-Cancer
- HDAC INHIBITORS CANCER VPA+ 5-Azacytidine+ATRA
- Download File
- RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors
- 2011/147588 Al
- WO 2014/071109 Al 8 May 20 14 (08.05.2014) W P O P CT